The activity of five novel gyrase inhibitors was evaluated against 303 nonduplicate Pseudomonas aeruginosa strains collected from 53 North American institutions. The most active compound, GP-2, displayed MIC 50 and MIC 90 values of 1 and 2 g/ml, respectively. Cross-resistance to other commercially available antipseudomonal compounds was not evident, as no major change was observed in the gyrase inhibitor MIC distribution when stratified by nonsusceptible phenotypes, including the fluoroquinolones and those isolates classified as multidrug resistant (MDR).
P
seudomonas aeruginosa is a well-recognized pathogen that is responsible for a considerable portion of the nosocomialbased Gram-negative infections. While this organism has historically been associated with intensive care unit (ICU)-derived infections, it is increasingly being recognized as an important cause of infection in the non-ICU setting (1) . In addition to its infectionrelated distribution in the hospital setting, this organism commonly exhibits a drug-resistant phenotypic profile that further complicates the clinical management of the infected patient (2) . This escalating resistance profile in P. aeruginosa has been observed among the most commonly utilized therapies: ␤-lactams (penicillins, cephalosporins, monobactams, and carbapenems), ␤-lactam-␤-lactam inhibitor combinations, aminoglycosides, and fluoroquinolones (1, 3) . A new class of dual-targeting inhibitors that target the bacterial DNA gyrase and topoisomerase IV at the ATP-binding subunits GyrB/ParE, thus avoiding the GyrA/ ParC-mediated fluoroquinolone resistance, has been developed by Trius Therapeutics (4, 5) . No agents in current clinical use target GyrB/ParE, minimizing the potential for cross-resistance with other antibiotics in the clinic. This new inhibitor class demonstrates broad-spectrum antibacterial activity against a wide range of Gram-positive and Gram-negative pathogens, including drug-resistant strains (6, 7) . In this study, we assessed the activity of 5 novel gyrase inhibitor compounds, GP-1, GP-2, GP-4, GP-5, and GP-6, against a panel of highly resistant P. aeruginosa isolates.
A total of 303 nonduplicate nonurine P. aeruginosa isolates collected from the respiratory tract, bloodstream, body fluid, and wounds were selected for antimicrobial susceptibility testing against the five gyrase inhibitor agents. The majority of P. aeruginosa isolates were collected at 53 sites throughout North America between 2007 and 2010 (1, 3). Forty-seven additional drug-resistant P. aeruginosa clinical isolates collected from respiratory specimens at our institution through 2011 that have been utilized in in vivo murine pharmacodynamic studies were also included (8) . The total cohort of P. aeruginosa isolates selected represented a range of susceptibilities encompassing major resistant phenotypes, including fluoroquinolone, carbapenem, ␤-lactam-␤-lactamase inhibitor combination, cephalosporin, aminoglycoside, and multidrug resistance.
The test agents were supplied as powders by Trius Therapeutics, San Diego, CA. Aqueous stock solutions were prepared in dimethyl sulfoxide, as compounds are not readily dissolved with water-based diluents. Renderings of the chemical structure for each of the gyrase inhibitor compounds are displayed in Fig. 1 .
Antimicrobial susceptibility testing was conducted using the broth microdilution methodology in the Clinical and Laboratory Standards Institute (CLSI) guidelines (9, 10). The gyrase compound stock solutions were diluted in cation-adjusted MuellerHinton broth and serially diluted in doubling dilutions (1:2) over a 512-fold concentration range. All P. aeruginosa isolates were tested singularly with each of the five gyrase inhibitor compounds.
Additional duplicate MIC testing was performed with the GP-1 and GP-6 compounds for all P. aeruginosa isolates using an abbreviated concentration range (based on previously obtained values). While no CLSI quality control ranges exist for these novel compounds, P. aeruginosa ATCC 27853 and P. aeruginosa PAO1 were utilized as quality control strains and fell within MIC ranges based on data established by Trius Therapeutics.
The P. aeruginosa isolates were stratified into nonsusceptible phenotypes to determine if cross-resistance to any relevant antimicrobial group was present. The stratified groups were fluoroquinolone (FQ) nonsusceptible (NS) (levofloxacin [LVX], Ն2 g/ml, and/or ciprofloxacin [CIP], Ն1 g/ml), carbapenem NS (meropenem [MEM] , Ն4 g/ml); ␤-lactam-␤-lactamase inhibitor combination NS (piperacillin-tazobactam [TZP], Ն32/4 g/ ml), cephalosporin NS (cefepime [FEP] , Ն16 g/ml, and/or ceftazidime [CAZ], Ն16 g/ml), aminoglycoside NS (tobramycin [TOB], Ն8 g/ml), and multidrug resistant (MDR; nonsusceptible to at least one antimicrobial agent from three different antimicrobial classes). This collection of P. aeruginosa isolates was highly resistant to the above-mentioned antimicrobial classes, as over 50% were MDR. Greater than 60% of these isolates were FQ, cephalosporin, and TZP NS. MIC frequencies and cumulative percentages for all P. aeruginosa isolates and phenotypic groups are listed in Table 1 . The majority (82%) of the MIC distributions were equivalent in each nonsusceptible phenotypic group for each gyrase inhibitor compound, and no change greater than a 2-fold difference was observed for any of the phenotypic groupings.
The MIC distributions, including range, median (and mode), MIC 50 , and MIC 90 , were calculated for each compound for all isolates. The MIC distributions for the five gyrase inhibitor com- .5) 0 (0.5) 3 (2.1) 13 (8.9) 50 (34. pounds as well as CIP and LVX are displayed in Fig. 2 . The most active compound against this group of P. aeruginosa strains was GP-2, with a median (mode) and MIC 50 of 1 and a MIC 90 equal to 2 g/ml. Compounds GP-5 and GP-6 were 2-fold less active, with a median (mode) and MIC 50 of 2 g/ml and a MIC 90 equal to 4 g/ml. The least-active compounds were GP-1 and GP-4, with a median (mode) and MIC 50 of 4 g/ml and MIC 90 values equal to 8 and 16 g/ml, respectively. The mode and MIC 50 for both CIP and LVX against these P. aeruginosa strains were 1 and 4 g/ml, respectively. Among the 189 FQ-NS isolates, the gyrase inhibitor compound exhibited 4-to 16-fold more activity than either CIP or LVX. MIC 90 values were 4 g/ml for GP-5, GP-6, and GP-2, 16 g/ml for GP-4 and GP-1, and 64 g/ml for both CIP and LVX. While the molecular characterization of the FQ resistance determinants was not investigated for these isolates, the MIC 50 /MIC 90 of the most active gyrase compounds GP-5, GP-6, and GP-2 were 2/4, 2/4, and 2/4 g/ml, respectively, against the 37 highly FQresistant isolates (MIC Ն 64 g/ml).
The highly resistant population of P. aeruginosa isolates incorporated in the current study provided a formidable challenge to the potency of these novel gyrase inhibitors. Thus, the phenotypic profile of these isolates would represent the worst-case scenario and a very small percentage of the overall P. aeruginosa population of most institutions at this time. Despite the resistance profile for other antimicrobial agents, the gyrase inhibitors displayed strong potency attributes, as the most active compound, GP-2, displayed MIC 50 and MIC 90 values of 1 and 2 g/ml, respectively. Moreover, the majority of MICs for these resistant P. aeruginosa strains were Յ4 g/ml for all five of the gyrase inhibitor compounds under study. Importantly, all of these gyrase inhibitors maintained their in vitro potency irrespective of the phenotypic profile to other anti-P. aeruginosa compounds, including the fluoroquinolones and those isolates classified as MDR. These novel gyrase inhibitor agents with alternative cellular targets may prove to be a future option for the treatment of P. aeruginosa.
